These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9531875)

  • 61. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency.
    Couzinet B; Lestrat N; Brailly S; Forest M; Schaison G
    J Clin Endocrinol Metab; 1988 Mar; 66(3):552-6. PubMed ID: 3127417
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.
    de Jong D; Macklon NS; Fauser BC
    Fertil Steril; 2000 May; 73(5):1051-4. PubMed ID: 10785238
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
    Paulson RJ; Sauer MV; Lobo RA
    J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration.
    Filicori M; Cognigni GE; Pocognoli P; Tabarelli C; Spettoli D; Taraborrelli S; Ciampaglia W
    Hum Reprod; 2002 Aug; 17(8):2009-15. PubMed ID: 12151429
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Elevated progesterone levels in the late follicular phase do not predict success of in vitro fertilization-embryo transfer.
    Abuzeid MI; Sasy MA
    Fertil Steril; 1996 May; 65(5):981-5. PubMed ID: 8612861
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone.
    Fleming R; Lloyd F; Herbert M; Fenwick J; Griffiths T; Murdoch A
    Hum Reprod; 1998 Jul; 13(7):1788-92. PubMed ID: 9740424
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Follicular monitoring and outcome of in vitro fertilization in gonadotropin-releasing hormone-agonist-treated cycles.
    Forman RG; Robinson J; Egan D; Ross C; Gosden B; Barlow DH
    Fertil Steril; 1991 Mar; 55(3):567-73. PubMed ID: 1900482
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gonadotropin, estrogen and progesterone response to long term gonadotropin-releasing hormone infusion at various stages of the menstrual cycle.
    Jewelewicz R; Dyrenfurth I; Ferin M; Bogumil J; Vande Wiele RL
    J Clin Endocrinol Metab; 1977 Oct; 45(4):662-7. PubMed ID: 334788
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization.
    Neveu S; Hedon B; Bringer J; Chinchole JM; Arnal F; Humeau C; Cristol P; Viala JL
    Fertil Steril; 1987 Apr; 47(4):639-43. PubMed ID: 3106101
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles.
    Romeu A; Monzó A; Peiró T; Diez E; Peinado JA; Quintero LA
    J Assist Reprod Genet; 1997 Oct; 14(9):518-24. PubMed ID: 9401870
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome.
    Loumaye E; Engrand P; Howles CM; O'Dea L
    Fertil Steril; 1997 May; 67(5):889-99. PubMed ID: 9130895
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Human urinary follicle-stimulating hormone and human menopausal gonadotropin in induction of multiple follicle growth and ovulation.
    Venturoli S; Orsini LF; Paradisi R; Fabbri R; Porcu E; Magrini O; Flamigni C
    Fertil Steril; 1986 Jan; 45(1):30-5. PubMed ID: 3080344
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization.
    Kovacs P; Kovats T; Kaali SG
    Fertil Steril; 2010 Feb; 93(2):475-9. PubMed ID: 19200991
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Endocrine responses to gonadotrophins after LHRH agonist administration on cycle days 1-4: prevention of premature luteinization.
    Martikainen H; Rönnberg L; Tapanainen J; Puistola U; Orava M; Kauppila A
    Hum Reprod; 1990 Apr; 5(3):246-9. PubMed ID: 2112552
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recombinant follicle-stimulating hormone versus human menopausal gonadotropin in the late follicular phase during ovarian hyperstimulation for in vitro fertilization.
    Commenges-Ducos M; Piault S; Papaxanthos A; Ribes C; Dallay D; Commenges D
    Fertil Steril; 2002 Nov; 78(5):1049-54. PubMed ID: 12413992
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.